| Identification | Back Directory | [Name]
5-(3-Benzyloxyphenyl)-7-[trans-3-[(pyrrolidin-1-yl)methyl]cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine | [CAS]
475488-23-4 | [Synonyms]
ADW
CS-467
ADW 742
NVP-ADW7
GSK 552602A
NVP-ADW742 b
NVP-ADW742(ADW742)
GSK 552602A; ADW742
ADW 742
GSK 552602A
5-(3-(Benzyloxy)phenyl)-7-((1r,3r)-3-(pyrrolidin-1-ylmethyl)-cyclobutyl)-7H-pyrrolo[2,3-d]pyri
5-(3-Benzyloxyphenyl)-7-[trans-3-[(pyrrolidin-1-yl)methyl]cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
5-[3-(Phenylmethoxy)phenyl]-7-[trans-3-(1-pyrrolidinylmethyl)cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-[3-(phenylmethoxy)phenyl]-7-[trans-3-(1-pyrrolidinylmethyl)cyclobutyl]-
5-(3-Benzyloxyphenyl)-7-[trans-3-[(pyrrolidin-1-yl)methyl]cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine USP/EP/BP
5-(3-Benzyloxyphenyl)-7-[trans-3-[(pyrrolidin-1-yl)methyl]cyclobutyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine NVP-ADW742 GSK 552602A | [Molecular Formula]
C28H31N5O | [MDL Number]
MFCD16038913 | [MOL File]
475488-23-4.mol | [Molecular Weight]
453.59 |
| Chemical Properties | Back Directory | [Boiling point ]
677.5±55.0 °C(Predicted) | [density ]
1.31 | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
crystalline solid | [pka]
10.00±0.20(Predicted) | [color ]
White to light yellow |
| Hazard Information | Back Directory | [Uses]
NVP-ADW742 is an IGF-1R inhibitor with IC50?of 0.17 μM. | [Biological Activity]
nvp-adw742 is a novel inhibitor of ifg-1receptor (igf-1r) kinase with the ic50 value of 0.17μm [1].nvp-adw742 has shown above 16-fold effective function against igf-1r than insulin receptor (insr). furthermore, nvp-adw742 has also been reported to inhibit other kinases , with the ic50 values of ＞10μm for her2, pdgfr, vegfr-2, or bcr-abl p210, and the ic50 values ＞5μm for c-kit [1]. besides, nvp-adw742 combined with etoposide and carboplatin has been reported to inhibit cell growth and induce cytotoxicity by mtt assay using the small cell lung cancer (sclc), including h526, h146, wba and h209 cell lines. in addition, nvp-adw742 has been revealed to completely inhibit the expression of vegf mrna which induced by igf-i in h526 cells [2]. | [in vivo]
NVP-ADW742 (ADW742; 10 mg/kg for IP or 50 mg/kg for orally; twice daily for 19 days) significantly suppresses tumor growth and prolongs the survival of mice[1].
| Animal Model: | 6- to 8-week-old male SCID/NOD mice with diffuse skeletal lesions of luciferase-expressing MM cells[1] | | Dosage: | 10 mg/kg (IP) or 50 mg/kg (orally) | | Administration: | IP or orally; twice daily for 19 days | | Result: | Significantly suppressed tumor growth and prolonged the survival of mice.
|
| [storage]
Store at -20°C | [References]
[1] mitsiades cs1, mitsiades ns, mcmullan cj, poulaki v, shringarpure r, akiyama m, hideshima t, chauhan d, joseph m, libermann ta, garcía-echeverría c, pearson ma, hofmann f, anderson kc, kung al. inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors . cancer cell. 2004 mar; 5(3):221-30.
[2]warshamana-greene gs1, litz j, buchdunger e, garcía-echeverría c, hofmann f, krystal gw. the insulin-like growth factor-i receptor kinase inhibitor, nvp-adw742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. clin cancer res. 2005 feb 15;11(4):1563-71. |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|